Testimonials

Background stories of how others approached and experienced their European Horizon funding trajectory.

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Published on | 1 month ago

Programmes Health

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.

Read the full article for details 
Other available testimonials

Testimonial

image of ERC grants for UGent professor Lieven Eeckhout

ERC grants for UGent professor Lieven Eeckhout

Professor Lieven Eeckhout’s main research interests include computer architecture and the hardware/software interface with a specific emphasis on performance evaluation and modeling, and dynamic resource management.

Professor Eeckhout is the recipient of a European Research Council (ERC) Starting grant, Advanced grant and three Proof of Concept grants. Two of his former PhD students founded in 2013 CoScale, a spin-off in data center monitoring, which was acquired by New Relic.